Drug Type Small molecule drug |
Synonyms + [4] |
Target |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (US) |
Molecular FormulaC22H23FN6OS |
InChIKeyAVIOBQFPAGEICQ-UHFFFAOYSA-N |
CAS Registry2070931-57-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | CN | 25 Jul 2022 | |
Advanced Gastric Adenocarcinoma | Phase 2 | CN | 01 Jun 2022 | |
Gastrooesophageal junction cancer | Phase 2 | CN | 01 Jun 2022 | |
Advanced gastric carcinoma | Phase 2 | CN | 16 Feb 2022 | |
Advanced Colorectal Adenocarcinoma | Phase 2 | CN | 31 Jan 2022 | |
Metastatic Colorectal Carcinoma | Phase 2 | CN | 31 Jan 2022 | |
Colorectal Cancer | Phase 2 | CN | 29 Nov 2021 | |
Refractory acute myeloid leukemia | Phase 2 | CN | 16 Sep 2021 | |
Relapsing acute myeloid leukemia | Phase 2 | CN | 16 Sep 2021 | |
Myelodysplastic Syndromes | Phase 2 | CN | 09 Sep 2021 |